Primary sclerosing cholangitis

DGAP-News: Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

Thursday, October 14, 2021 - 12:08pm

NEW YORK, October 14, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today.

Key Points: 
  • NEW YORK, October 14, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today.
  • "Patrick is a seasoned business development executive who has spent his career helping to successfully build a number of public biopharmaceutical companies.
  • He brings to Immunic extensive leadership in building companies through strategic partnerships and non-dilutive funding," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which time he worked on all aspects of business development.

Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

Thursday, October 14, 2021 - 11:30am

In this newly created role, Mr. Walsh will be responsible for business development, including strategic partnering opportunities, and will become part of the executive management team of Immunic.

Key Points: 
  • In this newly created role, Mr. Walsh will be responsible for business development, including strategic partnering opportunities, and will become part of the executive management team of Immunic.
  • "Patrick is a seasoned business development executive who has spent his career helping to successfully build a number of public biopharmaceutical companies.
  • He brings to Immunic extensive leadership in building companies through strategic partnerships and non-dilutive funding," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which time he worked on all aspects of business development.

BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005

Wednesday, October 13, 2021 - 12:00pm

We thank Maruho for its investment in BiomX and support of our atopic dermatitis program, said Jonathan Solomon, Chief Executive Officer of BiomX.

Key Points: 
  • We thank Maruho for its investment in BiomX and support of our atopic dermatitis program, said Jonathan Solomon, Chief Executive Officer of BiomX.
  • As the leading dermatology company in Japan, Maruho has built exceptional therapeutic capabilities and expertise that could support the success of BX005 in Japan.
  • BX005 is BiomXs topical phage product candidate targeting Staphylococcus aureus (S. aureus), a bacterium associated with the development and exacerbation of inflammation in atopic dermatitis.
  • Results from a Phase 1/2 proof-of-concept trial evaluating the safety and efficacy of BX005 in atopic dermatitis patients are expected in the first half of 2022.

CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan

Tuesday, October 12, 2021 - 1:30pm

Jadeite will be responsible for clinical development, regulatory approval and commercialization of odevixibat in Japan, where there is significant market opportunity.

Key Points: 
  • Jadeite will be responsible for clinical development, regulatory approval and commercialization of odevixibat in Japan, where there is significant market opportunity.
  • "This agreement reinforces Jadeite's commitment and vision to develop highly differentiated and innovative medicines to improve the health and quality of life of patients in Japan."
  • "The agreement allows for success of both companies, and we look forward to further collaboration with Jadeite."
  • "CBC remains steadfast in our commitment to widening access to medical care globally, and Jadeite is our cornerstone in Japan.

Pliant Therapeutics to Participate in Piper Sandler Lung Day

Thursday, October 7, 2021 - 1:06pm

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliants President and Chief Executive Officer, will participate in a virtual fireside chat as part of the Piper Sandler Lung Day on Friday, October 15, 2021, at 11:00 a.m.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliants President and Chief Executive Officer, will participate in a virtual fireside chat as part of the Piper Sandler Lung Day on Friday, October 15, 2021, at 11:00 a.m.
  • A replay of the Piper Sandler virtual fireside chat will be available on the Events & Presentations page of Pliants website following the conclusion of the event for 90 days.
  • Pliant is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.
  • Pliant is currently recruiting Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC.

Albireo Recognizes PFIC Awareness Day 2021

Tuesday, October 5, 2021 - 1:30pm

BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network (PFIC Network) in recognition of PFIC Awareness Day 2021, a global effort to support patients and families affected by progressive familial intrahepatic cholestasis (PFIC).

Key Points: 
  • BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network (PFIC Network) in recognition of PFIC Awareness Day 2021, a global effort to support patients and families affected by progressive familial intrahepatic cholestasis (PFIC).
  • Every year the PFIC Network recognizes, shares, and supports the PFIC community in hopes for a better future for those impacted by PFIC ( events.pfic.org/awareness-day-2021/ ).
  • This year, PFIC Network is working with the global community to recognize PFIC Awareness Day around the world through a variety of initiatives, including:
    Raising Awareness: Share your story and photos with the #ItchingForACure hashtag and your journey will help spread awareness around the world.
  • Guided by our mission of providing hope to families, we stand with the PFIC community in recognizing PFIC Awareness Day, said Ron Cooper, President and Chief Executive Officer of Albireo.

DGAP-News: Immunic, Inc. Enrolls First Patient in Its Phase 2 CALLIPER Trial of IMU-838 in Progressive Multiple Sclerosis

Thursday, September 30, 2021 - 12:08pm

The trial, which is intended to run concurrently with and as a complement to the company's twin phase 3 ENSURE trials in relapsing-remitting multiple sclerosis (RRMS), is focused on progressive forms of multiple sclerosis (MS) and designed to corroborate IMU-838's neuroprotective potential in this patient population.

Key Points: 
  • The trial, which is intended to run concurrently with and as a complement to the company's twin phase 3 ENSURE trials in relapsing-remitting multiple sclerosis (RRMS), is focused on progressive forms of multiple sclerosis (MS) and designed to corroborate IMU-838's neuroprotective potential in this patient population.
  • If the CALLIPER trial is successful in showing beneficial data, we believe this could be an essential differentiator for IMU-838 in the MS market."
  • Multiple sclerosis (MS) is an autoimmune disease that affects the brain, spinal cord and optic nerve.
  • Progressive multiple sclerosis (PMS) includes both primary progressive MS (PPMS) and secondary progressive MS (SPMS).

DGAP-News: Immunic, Inc. to Participate in Scientific and Investor Conferences in October

Tuesday, September 28, 2021 - 12:08pm

Three abstracts have been accepted for presentation, including a late-breaker on the company's lead asset IMU-838.

Key Points: 
  • Three abstracts have been accepted for presentation, including a late-breaker on the company's lead asset IMU-838.
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in a fireside chat.
  • Members of Immunic's business development and investor relations teams will participate in partnering activities at this conference.
  • Examples of such statements include, but are not limited to, statements relating to management's participation in scientific and investor conferences.

Immunic, Inc. to Participate in Scientific and Investor Conferences in October

Tuesday, September 28, 2021 - 11:30am

The poster presentations will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .

Key Points: 
  • The poster presentations will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in a fireside chat.
  • Members of Immunic's business development and investor relations teams will participate in partnering activities at this conference.
  • Examples of such statements include, but are not limited to, statements relating to management's participation in scientific and investor conferences.

Sirnaomics, Inc. to Present at TIDES USA 2021

Wednesday, September 22, 2021 - 2:00pm

The hybrid conference is taking place in person at the Boston Convention and Exhibition Center, and digitally on-demand, September 20-30.

Key Points: 
  • The hybrid conference is taking place in person at the Boston Convention and Exhibition Center, and digitally on-demand, September 20-30.
  • Presenter: Michael Molyneaux, MD, MBA, Chief Medical Officer at Sirnaomics, Inc.
  • Time/Date: 11:45am ET, Thursday, September 23, 2021.
  • The session will be available to watch on demand for attendees starting on September 28 for a 30-day period.